Where can I buy Windtree Therapeutics (Wint) stock?
Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Windtree Therapeutics' stock price today?
What is the upside for Windtree Therapeutics'stock?
Their forecasts range from $8.00 to $8.00. On average, they expect Windtree Therapeutics' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 451.7% from the stock's current price.
Where can I buy shares of Wint?
Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is windtree Therapeutics a good buy?
Windtree Therapeutics Inc (NASDAQ:WINT) The 2 analysts offering 12-month price forecasts for Windtree Therapeutics Inc have a median target of 3.40, with a high estimate of 3.80 and a low estimate of 3.00. The median estimate represents a +639.45% increase from the last price of 0.46.
Will Wint stock go up?
On average, Wall Street analysts predict that Windtree Therapeutics's share price could reach $3.40 by Jul 25, 2023. The average Windtree Therapeutics stock price prediction forecasts a potential upside of 826.43% from the current WINT share price of $0.37.
How has Windtree Therapeutics' stock price performed in 2022?
Windtree Therapeutics' stock was trading at $1.61 at the beginning of 2022. Since then, WINT shares have decreased by 73.3% and is now trading at $...
When is Windtree Therapeutics' next earnings date?
Windtree Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast fo...
How were Windtree Therapeutics' earnings last quarter?
Windtree Therapeutics, Inc. (NASDAQ:WINT) announced its quarterly earnings data on Thursday, May, 5th. The company reported ($0.29) EPS for the qua...
When did Windtree Therapeutics' stock split? How did Windtree Therapeutics' stock split work?
Shares of Windtree Therapeutics reverse split on Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The n...
Who are Windtree Therapeutics' key executives?
Windtree Therapeutics' management team includes the following people: Mr. Craig E. Fraser , Pres, CEO & Director (Age 57, Pay $584.62k) ( Linked...
Who are some of Windtree Therapeutics' key competitors?
Some companies that are related to Windtree Therapeutics include Cognition Therapeutics (CGTX) , Applied Genetic Technologies (AGTC) , Entera Bi...
What is Windtree Therapeutics' stock symbol?
Windtree Therapeutics trades on the NASDAQ under the ticker symbol "WINT."
Who are Windtree Therapeutics' major shareholders?
Windtree Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (1...
Which major investors are selling Windtree Therapeutics stock?
WINT stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View insider buying and selling ac...
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation
New Patent Provides Intellectual Property Protection Through Late 2039WARRINGTON, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
Windtree Is Studying Istaroxime in Early Cardiogenic Shock PatientsWARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced the results of U.S.
Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent
WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the third quarter ended September 30, 2021 and provided key business updates.
Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock
Anticipated New Patent Will Provide Intellectual Property Protection Until Late 2039WARRINGTON, Pa., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders
Tuesday, October 19th @ 8:00 am Eastern TimeWARRINGTON, Pa., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
What is the ticker symbol for Windtree Therapeutics?
WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc.
What is Windtree Therapeutics?
Windtree Therapeutics trades on the NASDAQ under the ticker symbol "WINT."
When will Windtree Therapeutics reverse split?
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.
Does Windtree Therapeutics pay dividends?
Windtree Therapeutics's stock reverse split on Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 28th 2020. An investor that had 100 shares of Windtree Therapeutics stock prior to the reverse split would have ...
What is Windtree Therapeutics?
Windtree Therapeutics does not currently pay a dividend.
Where is Windtree Therapeutics located?
Windtree Therapeutics, Inc., a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Transparency is our policy. Learn how it impacts everything we do
in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
What is Windtree Therapeutics?
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.
How long are futures trading delayed?
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company , which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute...
How to calculate restricted stock?
Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle.
How often do exchanges report short interest?
To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company's dividend expressed as a percentage of its current stock price.
Does WINT pay dividends?
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Who owns restricted shares of a company?
WINT is not currently paying a regular dividend.
Is index time real time?
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
News & Analysis: Windtree Therapeutics, Inc
Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Source: FactSet
Environmental, Social, and Governance Rating
There is no available coverage of Windtree Therapeutics, Inc. at this time.
